New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Revolution Medicines, Inc.

Contributing Author

Recent Articles by Revolution Medicines, Inc.

Sep-29	Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer RVMD GlobeNewswire
Sep-10	Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma RVMD GlobeNewswire
Aug-06	Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress RVMD GlobeNewswire
Jul-30	Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 RVMD GlobeNewswire
Jul-24	Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor RVMD GlobeNewswire
Jul-23	Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib RVMD GlobeNewswire
Jul-09	Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates RVMD GlobeNewswire
Jun-30	Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors RVMD GlobeNewswire
Jun-24	Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers RVMD GlobeNewswire
Jun-23	Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations RVMD GlobeNewswire
May-14	Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer RVMD GlobeNewswire
May-07	Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress RVMD GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.